However, the journey from bench to bedside is intricate and demands continued investigation, not only into the combined therapeutic potential of LNCs@CSF1R siRNA and anti-PD-1 but also into the broader implications of MDSC regulation in various cancer types. The gene discussed is CSF1R; the disease is cancer.